Efficacy of TCA Effect on Varicella Atrophic Scars

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified January 2007 by Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting

Sponsor:

Information provided by:

Shahid Beheshti University of Medical Sciences

ClinicalTrials.gov Identifier:

NCT00422539

First received: January 16, 2007

Last updated: NA

Last verified: January 2007

History: No changes posted

Purpose

This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella

Condition	Intervention	Phase
Atrophic Varicella Scar	Drug: 70% trichloroacetic acid	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars

Resource links provided by NLM:

MedlinePlus related topics: Chickenpox Scars Shingles

Drug Information available for: Trichloroacetic acid

U.S. FDA Resources

Further study details as provided by Shahid Beheshti University of Medical Sciences:

Primary Outcome Measures:

Objective Clearance(before and after photographies were taken)

Secondary Outcome Measures:

Subjective Clearance(according to the patients satisfaction)
Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)


Estimated Enrollment:	100
Study Start Date:	March 2006

Detailed Description:

high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars. According to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; We aimed to answer that whether we could achieve the same results from 70% TCA on atrophic varicella scars.

Eligibility


Ages Eligible for Study:	15 Years to 45 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Atrophic varicella scar on face

Exclusion Criteria:

Active varicella infection
Active Herpetic infection
Previous history of keloid formation

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00422539

Contacts


Contact: Behrooz Barikbin, M.D.	98-21-22744393 ext 5	bbarikbin@yahoo.com

Locations


Iran, Islamic Republic of
Skin Research Center, Shohada-e Tajrish Hospital, shaheed Beheshti Medical University	Recruiting
Tehran, Iran, Islamic Republic of, 198994148

Sponsors and Collaborators

Shahid Beheshti University of Medical Sciences

Investigators


Study Chair:	Parviz Toossi, M.D.	Skin Research Center of Shaheed Beheshti medical University
Principal Investigator:	Behrooz Barikbin, M.D.	Skin Research Center of Shaheed Beheshti Medical Universty

More Information


ClinicalTrials.gov Identifier:	NCT00422539 History of Changes
Other Study ID Numbers:	SRC-BBA-1385-6-1
Study First Received:	January 16, 2007
Last Updated:	January 16, 2007

Keywords provided by Shahid Beheshti University of Medical Sciences:


trichloroacetic acid varicella scar

Additional relevant MeSH terms:


Chickenpox Herpes Zoster Atrophy Herpesviridae Infections	DNA Virus Infections Virus Diseases Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on June 23, 2017

To Top